The Serum Institute of India (SII) based in Pune in India has currently stopped the trial of Oxford’s coronavirus vaccine. A trial will be banned until further instructions from the Drug Controller General of India. This trial has been stopped due to security reasons.
The initial results of the trial of the Corona vaccine being developed by Oxford University and AstraZeneca PLC have been very encouraging. However, trials in Britain and the United States were halted after a volunteer fell ill in Britain. The CEO of Serum Institute, Adar Poonawala, said that this would not affect the vaccine trials in India. Subsequently, the Drugs Control General of India issued a notice to the Serum Institute of India and questioned why Serum did not inform the DGCI about the results of the ongoing trials in other countries.
Trials of the second and third phase of the Oxford vaccine are being conducted at 17 places in India. However, after receiving DCGI’s notice, Serum Institute has decided to stop the trial.
During the trial, a volunteer in the UK was diagnosed with transverse myelitis, an inflammatory syndrome affecting the spinal cord, for which viral infection may be responsible. An independent investigation is being conducted to find the cause.
The decision to resume the trial will be taken by the Medicine and Healthcare Products Regulatory Agency (MHRA).
According to savants, such breaks are only part of the vaccine trials. A vaccine expert from Delhi AIIMS said, “On some occasions it happens that the patient gets sick or sometimes even dies during the vaccine dose. This is a process and trials need to be stopped. Trial investigators are following the entire ethical standard. “